Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma.
Completed · Phase 2
Conditions studied: Nodular Basal Cell Carcinoma
In brief
This Phase 2 study evaluates the safety and efficacy of microneedle array (MNA) alone and in combination with two dose levels of doxorubicin (100µg and 200µg) in patients with nodular basal cell carcinoma. Efficacy is assessed using both clinical (visual) and histological endpoints, which together provide a comprehensive evaluation of lesion response.
Key facts
- Study ID
- NCT06608238
- Run by
- SkinJect, Inc.
- People needed
- 90
- Starts
- 2024-09-03
- Expected to finish
- 2026-03-13
- Last updated by the study team
- 2026-05-04
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Rao Dermotology West Coast -Site #4 — Fresno, California, United States
- Paradigm Research -Site #6 — San Diego, California, United States
- Therapeutics Clinical Research -site 08 — San Diego, California, United States
- Oak Dermotology - site 07 — Naperville, Illinois, United States
- Arlington Dermatology - Site #1 — Rolling Meadows, Illinois, United States
- Clinical Trials Management, LLC- Site #5 — Mandeville, Louisiana, United States
- Rao Dermatology - Site #3 — Highlands, New Jersey, United States
- HIckory Dermatology Research Center — Hickory, North Carolina, United States
- American Skin and Cancer Center - Site#2 — Knoxville, Tennessee, United States
- Virginia Clinical Research Inc - site 11 — Norfolk, Virginia, United States
- Nottingham University Hospitals NHS Trust — Nottingham, East Midlands, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.